185.30
price down icon0.10%   -0.19
pre-market  시장 영업 전:  185.55   0.25   +0.13%
loading

Abbvie Inc 주식(ABBV)의 최신 뉴스

pulisher
Jun 18, 2025

AbbVie (NYSE:ABBV) migraine drug update boosts biotech pipeline strength S&P 500 - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie's migraine drug meets main goal in head-to-head study with topiramate - Reuters

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie’s atogepant achieves superiority in migraine prevention - The Pharma Letter

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - PharmaLive

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie (ABBV) Sees Success with Migraine Drug Atogepant in Late-Stage Trial - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Stock (ABBV) Dips: A Buying Opportunity for its 3.55% Dividend Yield? - Daily Chhattisgarh News

Jun 18, 2025
pulisher
Jun 18, 2025

Hidradenitis Suppurativa Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | InflaRx, Novartis, UCB, AbbVie, Pfizer, Amgen, Incyte, CSL Behring - Barchart.com

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie succeeds in late-stage migraine treatment trial (ABBV) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie’s migraine drug meets main goal of late-stage study - 1470 & 100.3 WMBD

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie (ABBV) Reports Positive Results from Migraine Study | ABBV Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Reports Positive Topline Results From Phase 3 TEMPLE Study Of Atogepant For Migrane - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Announces New Data Demonstrating Atogepant Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention - Investing News Network

Jun 18, 2025
pulisher
Jun 18, 2025

Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie’s atogepant shows superior results in migraine prevention trial By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention | ABBV St - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

AbbVie's migraine drug meets main goal of late-stage study - TradingView

Jun 18, 2025
pulisher
Jun 17, 2025

Here's Why AbbVie (ABBV) Fell More Than Broader Market - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie’s $1.6 Billion Break Fee Sidesteps Capital Loss Limit (1) - news.bloombergtax.com

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - Investing News Network

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie (ABBV) Faces Potential Challenges Amid U.S. Advertising P - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

RFK Jr. plans crackdown on pharma ads in threat to AbbVie's $2 billion marketing strategy - Crain's Chicago Business

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow (NYSE:ABBV) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C - Insider Monkey

Jun 17, 2025
pulisher
Jun 16, 2025

AbbVie says blood cancer drug fails late-stage trial - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Sector Update: Health Care Stocks Retreat Late Afternoon - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Sector Update: Health Care - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie cancer drug misses the mark in trial for new use - Crain's Chicago Business

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) and Genentech Report Phase III Study Results for Venclexta | ABBV Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) Faces Setback in VERONA Study for Venclexta | ABBV Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie stock dips after cancer drug trial setback - TradingView

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) Faces Setback with Leukemia Drug Trial - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie fails in late-stage trial for Roche-partnered blood cancer therapy venetoclax - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie: trial fails in myelodysplastic syndrome - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie's Venetoclax Doesn't Meet Primary Endpoint in Trial for Higher-Risk Myelodysplastic Syndrome Treatment - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Here's Why AbbVie (ABBV) is a Strong Value Stock - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Says Myelodysplastic Syndrome Phase 3 Trial Failed to Meet Primary Endpoint - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Provides Update on VERONA Trial for Newly Diagnosed Highe - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie (ABBV) Phase 3 Trial on Myelodysplastic Syndrome Falls Short | ABBV Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie’s venetoclax fails in phase 3 trial for MDS treatment By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

5 Large Drug Stocks That Are Poised to Ride on Sector Recovery - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Provides Update On VERONA Trial For Newly Diagnosed Higher-Risk Myelodysplastic Syndromes - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie's Phase 3 VERONA Trial Falls Short: Key Results for Venetoclax MDS Treatment Revealed - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie: Margin Clarity, Dividend Durability Awaited (NYSE:ABBV) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie, Chicago Cubs step up to plate to hit a cancer research grand slam - Medical Marketing and Media

Jun 16, 2025
pulisher
Jun 16, 2025

AbbVie Moves From Blockbuster Loss To Market Domination (NYSE:ABBV) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 15, 2025

AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth (NYSE:ABBV) - Seeking Alpha

Jun 15, 2025
pulisher
Jun 15, 2025

AbbVie's Post-Humira Strategy Is Paying Off For Investors (NYSE:ABBV) - Seeking Alpha

Jun 15, 2025
pulisher
Jun 15, 2025

AbbVie Unethical Marketing Scandal: Department of Pharmaceuticals Refuses to Name Doctors - Daily Chhattisgarh News

Jun 15, 2025
pulisher
Jun 15, 2025

USFDA approves expanded indication for AbbVie Mavyret for Acute Hepatitis C Virus - Medical Dialogues

Jun 15, 2025
pulisher
Jun 13, 2025

Pharma dept refuses to name 30 docs penalised for Paris, Monaco trip - The New Indian Express

Jun 13, 2025
pulisher
Jun 13, 2025

AbbVie Sues Colo. Over State Discount Drug Law - Law360

Jun 13, 2025
pulisher
Jun 13, 2025

Dividend Stock Portfolio For Retirement - Insider Monkey

Jun 13, 2025
pulisher
Jun 13, 2025

AbbVie Secures FDA Approval to Expand Mavyret’s Label - MSN

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves label expansion of AbbVie hepatitis C therapy - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Kalkine: Can FDA Approval Reshape AbbVie’s Role In S&P 500 - Kalkine Media

Jun 12, 2025
pulisher
Jun 12, 2025

AbbVie (NYSE:ABBV) Achieves FDA Approval for MAVYRET Label Expansion to Treat Pediatric Hepatitis C - Yahoo Finance

Jun 12, 2025
drug_manufacturers_general NVO
$73.77
price down icon 0.32%
drug_manufacturers_general JNJ
$149.79
price down icon 0.62%
drug_manufacturers_general NVS
$115.77
price down icon 0.16%
drug_manufacturers_general MRK
$79.06
price down icon 0.29%
$289.33
price down icon 0.10%
자본화:     |  볼륨(24시간):